Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-07 4:07 pm Purchase |
2025-03-05 | 13D | Elicio Therapeutics, Inc. ELTX |
Yekaterina Chudnovsky | 9,657,539 48.100% |
9,657,539 (New Position) |
Filing History |
| 2025-02-05 11:10 am Purchase |
2025-01-30 | 13G | Elicio Therapeutics, Inc. ELTX |
Knoll Capital Management LLC | 630,915 5.200% |
630,915 (New Position) |
Filing History |
| 2025-01-07 4:30 pm Purchase |
2023-12-08 | 13G | Elicio Therapeutics, Inc. ELTX |
Actyus Private Equity SGIIC, S.A. | 587,818 5.450% |
587,818 (New Position) |
Filing History |
| 2024-08-14 5:01 pm Purchase |
2024-08-12 | 13D | Elicio Therapeutics, Inc. ELTX |
GKCC LLC | 5,595,108 38.700% |
3,442,341 (+159.90%) |
Filing History |
| 2024-07-02 4:39 pm Purchase |
2024-06-28 | 13D | Elicio Therapeutics, Inc. ELTX |
GKCC LLC | 2,152,767 19.990% |
109,587 (+5.36%) |
Filing History |
| 2024-04-10 4:01 pm Sale |
2024-04-08 | 13D | Elicio Therapeutics, Inc. ELTX |
Clal Biotechnology Industries Ltd. | 481,727 4.680% |
-117,470 (-19.60%) |
Filing History |
| 2024-03-20 9:07 pm Sale |
2024-03-18 | 13D | Elicio Therapeutics, Inc. ELTX |
Clal Biotechnology Industries Ltd. | 599,197 5.830% |
-90,372 (-13.11%) |
Filing History |
| 2024-03-20 4:37 pm Purchase |
2024-03-19 | 13D | Elicio Therapeutics, Inc. ELTX |
GKCC LLC | 2,043,180 19.990% |
123,016 (+6.41%) |
Filing History |
| 2023-12-27 4:07 pm Unchanged |
2023-12-22 | 13D | Elicio Therapeutics, Inc. ELTX |
Clal Biotechnology Industries Ltd. | 689,569 7.120% |
0 (Unchanged) |
Filing History |
| 2023-12-26 4:25 pm Purchase |
2023-12-22 | 13D | Elicio Therapeutics, Inc. ELTX |
GKCC LLC | 1,920,164 19.990% |
1,213,000 (+171.53%) |
Filing History |
| 2023-08-30 5:16 pm Unchanged |
2023-08-28 | 13D | Elicio Therapeutics, Inc. ELTX |
Clal Biotechnology Industries Ltd. | 689,569 8.160% |
0 (Unchanged) |
Filing History |
| 2023-07-07 09:17 am Purchase |
2023-07-06 | 13G | Elicio Therapeutics, Inc. ELTX |
Vifor (International) Ltd. | 199,564 0.020% |
199,564 (New Position) |
Filing History |
| 2023-06-14 4:04 pm Purchase |
2023-06-01 | 13D | Elicio Therapeutics, Inc. ELTX |
Elicio Therapeutics Inc. ELTX |
319,527 3.700% |
319,527 (New Position) |
Filing History |
| 2023-06-14 2:42 pm Purchase |
2023-06-01 | 13D | Elicio Therapeutics, Inc. ELTX |
GKCC LLC | 707,164 8.400% |
707,164 (New Position) |
Filing History |
| 2023-06-12 4:01 pm Purchase |
2023-06-09 | 13D | Elicio Therapeutics, Inc. ELTX |
Clal Biotechnology Industries Ltd. | 689,569 7.110% |
689,569 (New Position) |
Filing History |
| 2023-02-14 4:23 pm Purchase |
2022-12-31 | 13G | Angion Biomedica Corp. ANGN |
Goldberg Itzhak | 180,929 6.000% |
180,929 (New Position) |
Filing History |
| 2023-02-14 12:12 pm Unchanged |
2022-12-31 | 13G | Angion Biomedica Corp. ANGN |
EISA-ABC LLC | 172,224 5.700% |
0 (Unchanged) |
Filing History |
| 2023-02-10 4:53 pm Purchase |
2022-12-31 | 13G | Angion Biomedica Corp. ANGN |
SATTERFIELD THOMAS A JR | 221,338 7.350% |
63,884 (+40.57%) |
Filing History |
| 2022-05-19 10:04 am Purchase |
2022-05-17 | 13G | Angion Biomedica Corp. ANGN |
SATTERFIELD THOMAS A JR | 157,455 5.300% |
157,455 (New Position) |
Filing History |
| 2022-04-27 4:10 pm Sale |
2021-12-31 | 13G | Angion Biomedica Corp. ANGN |
Elicio Therapeutics Inc. ELTX |
181,512 6.000% |
-108,662 (-37.45%) |
Filing History |